303 related articles for article (PubMed ID: 36161043)
1. Potassium-competitive acid blockers and gastroesophageal reflux disease.
Leowattana W; Leowattana T
World J Gastroenterol; 2022 Jul; 28(28):3608-3619. PubMed ID: 36161043
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic treatment of GERD: Where we are now, and where are we going?
Scarpignato C; Hongo M; Wu JCY; Lottrup C; Lazarescu A; Stein E; Hunt RH
Ann N Y Acad Sci; 2020 Dec; 1482(1):193-212. PubMed ID: 32935346
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
[TBL] [Abstract][Full Text] [Related]
4. The pharmacotherapeutic management of gastroesophageal reflux disease (GERD).
Chapelle N; Ben Ghezala I; Barkun A; Bardou M
Expert Opin Pharmacother; 2021 Feb; 22(2):219-227. PubMed ID: 32893683
[TBL] [Abstract][Full Text] [Related]
5. Novel Therapies for Gastroesophageal Reflux Disease: Beyond Proton Pump Inhibitors.
Shibli F; Kitayama Y; Fass R
Curr Gastroenterol Rep; 2020 Mar; 22(4):16. PubMed ID: 32185589
[TBL] [Abstract][Full Text] [Related]
6. Acid suppression therapy: where do we go from here?
Scarpignato C; Pelosini I; Di Mario F
Dig Dis; 2006; 24(1-2):11-46. PubMed ID: 16699262
[TBL] [Abstract][Full Text] [Related]
7. Esophageal mucosal breaks in gastroesophageal reflux disease partially responsive to proton pump inhibitor therapy.
Shaheen NJ; Denison H; Björck K; Silberg DG
Am J Gastroenterol; 2013 Apr; 108(4):529-34. PubMed ID: 23318482
[TBL] [Abstract][Full Text] [Related]
8. Gastroesophageal reflux disease in primary care: using changes in proton pump inhibitor therapy as an indicator of partial response.
Ruigómez A; Johansson S; Wernersson B; Fernández Cantero O; García Rodríguez LA
Scand J Gastroenterol; 2012 Jul; 47(7):751-61. PubMed ID: 22519917
[TBL] [Abstract][Full Text] [Related]
9. Association of Acute Gastroesophageal Reflux Disease With Esophageal Histologic Changes.
Dunbar KB; Agoston AT; Odze RD; Huo X; Pham TH; Cipher DJ; Castell DO; Genta RM; Souza RF; Spechler SJ
JAMA; 2016 May; 315(19):2104-12. PubMed ID: 27187303
[TBL] [Abstract][Full Text] [Related]
10. The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease.
Scarpignato C; Hunt RH
Curr Opin Gastroenterol; 2019 Jul; 35(4):344-355. PubMed ID: 31045597
[TBL] [Abstract][Full Text] [Related]
11. Randomized controlled trial of transoral incisionless fundoplication vs. proton pump inhibitors for treatment of gastroesophageal reflux disease.
Witteman BP; Conchillo JM; Rinsma NF; Betzel B; Peeters A; Koek GH; Stassen LP; Bouvy ND
Am J Gastroenterol; 2015 Apr; 110(4):531-42. PubMed ID: 25823768
[TBL] [Abstract][Full Text] [Related]
12. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
[TBL] [Abstract][Full Text] [Related]
13. ARE THE PERSISTENT SYMPTOMS TO PROTON PUMP INHIBITOR THERAPY DUE TO REFRACTORY GASTROESOPHAGEAL REFLUX DISEASE OR TO OTHER DISORDERS?
Azzam RS
Arq Gastroenterol; 2018 Nov; 55Suppl 1(Suppl 1):85-91. PubMed ID: 30304291
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic work-up of GERD.
Vela MF
Gastrointest Endosc Clin N Am; 2014 Oct; 24(4):655-66. PubMed ID: 25216910
[TBL] [Abstract][Full Text] [Related]
15. Results of short-and long-term medical treatment of gastroesophageal reflux disease (GERD).
Pohle T; Domschke W
Langenbecks Arch Surg; 2000 Aug; 385(5):317-23. PubMed ID: 11026702
[TBL] [Abstract][Full Text] [Related]
16. Multimodality evaluation of patients with gastroesophageal reflux disease symptoms who have failed empiric proton pump inhibitor therapy.
Galindo G; Vassalle J; Marcus SN; Triadafilopoulos G
Dis Esophagus; 2013 Jul; 26(5):443-50. PubMed ID: 22862422
[TBL] [Abstract][Full Text] [Related]
17. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of potassium-competitive acid inhibitors in the treatment of gastroesophageal reflux: a systematic review and meta-analysis.
Zhou X; Duan H; Li Q; Wang Q; Sun X
Scand J Gastroenterol; 2024 Jul; 59(7):788-797. PubMed ID: 38741565
[TBL] [Abstract][Full Text] [Related]
19. The early therapeutic response at 2 weeks is a crucial predictor of proton pump inhibitor-refractory gastroesophageal reflux disease.
Ogawa M; Arihiro S; Matsuhashi N; Joh T; Higuchi K; Iwakiri K; Kamiya T; Manabe N; Isshi K; Nakada T; Hokari A; Saruta M; Oshio A; Haruma K; Nakada K
Esophagus; 2021 Apr; 18(2):398-406. PubMed ID: 33136239
[TBL] [Abstract][Full Text] [Related]
20. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy.
Kusano M; Hosaka H; Kawamura O; Kawada A; Kuribayashi S; Shimoyama Y; Yasuoka H; Mizuide M; Tomizawa T; Sagawa T; Sato K; Yamada M
J Gastroenterol; 2015 Mar; 50(3):298-304. PubMed ID: 24919745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
